MMJ International Holdings distinguishes itself by adhering strictly to federal regulations at every stage of its R&D process. Rather than cutting corners, the company ensures its FDA clinical trials for its proprietary soft gelatin capsule-blending THC, CBD, and other phytocannabinoids, has meet the highest standards set by federal law. This commitment not only minimizes regulatory risks but also enhances MMJ's credibility with government agencies and leading healthcare institutions.